Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
Programmed death ligand 1 signals in cancer cells
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance
X Ma, S Jia, G Wang, M Liang, T Guo, H Du… - Signal transduction and …, 2023 - nature.com
Immune checkpoint blockade (ICB) offers a new opportunity for treatment for gastric cancer
(GC). Understanding the upstream regulation of immune checkpoints is crucial to further …
(GC). Understanding the upstream regulation of immune checkpoints is crucial to further …
High endothelial venules (HEVs) in immunity, inflammation and cancer
L Blanchard, JP Girard - Angiogenesis, 2021 - Springer
High endothelial venules (HEVs) are specialized blood vessels mediating lymphocyte
trafficking to lymph nodes (LNs) and other secondary lymphoid organs. By supporting high …
trafficking to lymph nodes (LNs) and other secondary lymphoid organs. By supporting high …
All‐in‐one biomimetic nanoplatform based on hollow polydopamine nanoparticles for synergistically enhanced radiotherapy of colon cancer
Even though radiotherapy is the most important therapeutic strategy for colon cancer
treatment, there is an enormous demand to improve radiosensitivity in solid tumor …
treatment, there is an enormous demand to improve radiosensitivity in solid tumor …
Current insight into the regulation of PD-L1 in cancer
Z Liu, X Yu, L Xu, Y Li, C Zeng - Experimental hematology & oncology, 2022 - Springer
The molecular mechanisms underlying cancer immune escape are a core topic in cancer
immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by …
immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by …
[HTML][HTML] Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
S Yin, Z Chen, D Chen, D Yan - Theranostics, 2023 - ncbi.nlm.nih.gov
Immunotherapy has achieved great success recently and opened a new avenue for anti-
tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) …
tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) …
Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Z Zhou, H Wang, J Li, X Jiang, Z Li, J Shen - International Journal of …, 2024 - Elsevier
Currently, immune checkpoint blockade (ICB) therapies that target the programmed cell
death ligand-1 (PD-L1) have been used as revolutionary cancer treatments in the clinic …
death ligand-1 (PD-L1) have been used as revolutionary cancer treatments in the clinic …
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
J Li, Z Xiao, D Wang, L Jia, S Nie, X Zeng, W Hu - Molecular Cancer, 2023 - Springer
Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …